Economic burden of sickle cell disease in Australia
While the estimated prevalence of SCD in Australia resulted in a relatively small total cost, the per patient annual cost of SCD remains high. This cost of SCD is anticipated to increase alongside migration and improved treatment. There are policies that could enhance patients' quality of life, thereby mitigating both economic and health burdens.
Authors
- Adam Irving (ORCID: https://orcid.org/0000-0002-0406-658X)
- P. Joy Ho (ORCID: https://orcid.org/0000-0002-2811-8671)
- Melissa J. Chee (ORCID: https://orcid.org/0000-0003-3815-9095)
- Anthea Greenway
- Neil Waters (ORCID: https://orcid.org/0000-0002-8012-1827)
- Tom Roberts (ORCID: https://orcid.org/0000-0003-4991-974X)
- Mwayi Kachapila (ORCID: https://orcid.org/0000-0002-8427-5612)
- Zane Kaplan (ORCID: https://orcid.org/0000-0001-7689-9997)
- Kylie D. Mason (ORCID: https://orcid.org/0000-0002-6238-4092)
- Erica M. Wood (ORCID: https://orcid.org/0000-0001-7527-2340)
- Dennis Petrie (ORCID: https://orcid.org/0000-0002-3882-2531)
- Helen E Haysom
- Cameron Wellard (ORCID: https://orcid.org/0000-0002-6115-5394)
- Zoe McQuilten (ORCID: https://orcid.org/0000-0001-9698-7185)
- Anna Nelson (ORCID: https://orcid.org/0000-0001-7589-5564)
- Steve Nwokeocha (ORCID: https://orcid.org/0009-0003-1014-6273)
Institutions
- The University of Sydney (AU)
- The Royal Melbourne Hospital (AU)
- Royal Children's Hospital (AU)
- Royal Prince Alfred Hospital (AU)
- Peter MacCallum Cancer Centre (AU)
- Monash Health (AU)
- Alfred Health (AU)
- Monash University (AU)
- University of Birmingham (GB)
Publication Details
- Journal
- Internal Medicine Journal
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1111/imj.70092
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Government of the United Kingdom
- Monash University
- Medical Research Council
- National Health and Medical Research Council